Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide

Biochemical Pharmacology

Volumn 78, Issue 12, 2009, Pages 1483-1490

  Zharikova, Olga L ^a   Fokina, Valentina M ^a   Nanovskaya, Tatiana N ^a   Hill, Ronald A ^b   Mattison, Donald R ^c   Hankins, Gary D V ^a   Ahmed, Mahmoud S ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF LOUISIANA AT MONROE   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Enzymes; Glyburide; Glyburide metabolism; Human liver; Human placenta

Indexed keywords

4 METHYLPYRAZOLE; ALPHA NAPHTHOFLAVONE; AROMATASE; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DRUG METABOLITE; FORMESTANE; GLIBENCLAMIDE; KETOCONAZOLE; LANSOPRAZOLE; QUINIDINE; SULFAPHENAZOLE; TROLEANDOMYCIN;

ARTICLE; CONTROLLED STUDY; DRUG COMPETITION; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME ANALYSIS; FEMALE; FETUS CIRCULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER MICROSOME; PLACENTA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBODIES; CROSS REACTIONS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GLYBURIDE; HUMANS; ISOENZYMES; LIVER; MICROSOMES; MICROSOMES, LIVER; PLACENTA; PREGNANCY;

EID: 70349989948     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.08.003     Document Type: Article

References (42)

1. Langer O., Conway D.L., Bercus M.D., Xenakis E.M.-J., and Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 343 (2000) 1134-1138
2. Jacobson G.F., Ramos G.A., Ching J.Y., Kirby R.S., Ferrara A., and Field R. Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. Am J Obstet Gynecol 193 (2005) 118-124
3. Hebert M.F., Ma X., Naraharisetti S.B., Krudys K.M., Umans J., Hankins G.D.V., et al. Are we optimizing gestational diabetes treatment with glyburide? The pharmacologic basis for better clinical practice. Clin Pharmacol Ther 85 (2009) 607-614
4. Nanovskaya T.N., Nekhayeva I., Hankins G.D.V., and Ahmed M.S. Effect of human serum albumin on transplacental transfer of glyburide. Biochem Pharmacol 72 (2006) 632-639
5. Nanovskaya T.N., Patrikeeva S., Hemauer S., Fokina V., Mattison D., Hankins G.D., et al. Effect of albumin on transplacental transfer and distribution of rosiglitazone and glyburide. J Matern Fetal Neonatal Med 21 (2008) 197-207
6. Ravindran S., Zharikova O.L., Hill R.A., Nanovskaya T.N., Hankins G.D., and Ahmed M.S. Identification of glyburide metabolites formed by hepatic and placental microsomes of humans and baboons. Biochem Pharmacol 72 (2006) 1730-1737
7. Zharikova O.L., Ravindran S., Nanovskaya T.N., Hill R.A., Hankins G.D.V., and Ahmed M.S. Kinetics of glyburide metabolites by hepatic and placental microsomes of humans and baboons. Biochem Pharmacol 73 (2007) 2012-2019
8. Rupp W., Christ O., and Heptner W. Resorption, excretion and metabolism after intravenous and oral administration of HB 419-14C in man. Arzneimittelforschung 19 (1969) 1428-1434 [in German]
9. Fuccella L.M., Tamassia V., and Valzelli G. Metabolism and kinetics of the hypoglycemic agent glipizide in man-comparison with glibenclamide. J Clin Pharmacol 13 (1973) 68-75
10. Balant L., Fabre J., and Zahnd G.R. Comparison of the pharmacokinetics of glipizide and glibenclamide in man. Eur J Clin Pharmacol 8 (1975) 63-69
11. Rydberg T., Wǻhlin-Boll E., and Melander A. Determination of glibenclamide and its two major metabolites in human serum and urine by column liquid chromatography. J Chromatogr 564 (1991) 223-233
12. Rydberg T., Jönsson A., Karisson M.O., and Melander A. Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. Br J Clin Pharmacol 43 (1997) 373-381
13. Jönsson A., Hallengren B., Rydberg T., and Melander A. Effects and serum levels of glibenclamide and its active metabolites in patients with type 2 diabetes. Diabetes Obes Metab 3 (2001) 403-409
14. Tiller P.R., Land A.P., Jardine I., Murphy D.M., Sozio R., Ayrton A., et al. Application of liquid chromatography-mass spectrometry analyses to the characterization of novel glyburide metabolites formed in vitro. J Chromatogr A 794 (1998) 15-25
15. Kirchheiner J., Brockmöller J., Meineke I., Bauer S., Rohde W., Meisel C., et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers. Clin Pharmacol Ther 71 (2002) 286-296
16. Niemi M., Cascorbi I., Timm R., Kroemer H.K., Neuvonen P.J., and Kivistö K.T. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 72 (2002) 326-332
17. Yin O.Q.P., and Tomlinson B. Chow MSS. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. Clin Pharmacol Ther 78 (2005) 370-377
18. Van Giersbergen P.L., Treiber A., Clozel M., Bodin F., and Dingemanse J. In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide. Clin Pharmacol Ther 71 (2002) 253-262
19. Naritomi Y., Terashita S., and Kagayama A. Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate. Xenobiotica 34 (2004) 415-427
20. Fischer V., Rodríguez-Gascón A., Heitz F., Tynes R., Hauck C., Cohen D., et al. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite. Drug Metab Dispos 26 (1998) 802-811
21. Hill R.A., Rudra S., Peng B., Roane D.S., Bounds J.K., Zhang Y., et al. Hydroxyl-substituted sulfonylureas as potent inhibitors of specific [3H] glyburide binding to rat brain synaptosomes. Bioorg Med Chem 11 (2003) 2099-2113
22. Nanovskaya T.N., Deshmukh S.V., Nekhayeva I.A., Zharikova O.L., Hankins G.D., and Ahmed M.S. Methadone metabolism by human placenta. Biochem Pharmacol 68 (2004) 583-591
23. Newton D.J., Wang R.W., and Lu A.Y.H. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23 (1995) 154-158
24. Bourrie M., Meunier V., Berger Y., and Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human microsomes. J Pharmacol Exp Ther 277 (1996) 321-332
25. Rodrigues A.D. Integrated cytochrome P450 reaction phenotyping. Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57 (1999) 465-480
26. Sai Y., Dai R., Yang T.J., Krausz K.W., Gonzalez F.J., Gelboin H.V., et al. Assessment of specificity of eight chemical inhibitors using cDNA-expressed cytochromes P450. Xenobiotica 30 (2000) 327-343
27. Stresser D.M., Turner S.D., McNamara J., Stocker P., Miller V.P., Crespi C.L., et al. A high-throughput screen to identify inhibitors of aromatase (CYP19). Anal Biochem 284 (2000) 427-430 [it is added for a-napht]
28. Li X.Q., Andersson T.B., Ahlström, and Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 32 (2004) 821-827
29. Groop L.C., Barzilai N., Ratheiser K., Luzi L., Wåhlin-Boll E., Melander A., et al. Dose-dependent effects of glyburide on insulin secretion and glucose uptake in humans. Diabetes Care 14 (1991) 724-727
30. Niemi M., Backman J.T., Neuvonen M., Neuvonen P.J., and Kivistö K.T. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin Pharmacol Ther 69 (2001) 400-406
31. Rae J.M., Johnson M.D., Lippman M.E., and Flockhart D.A. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 299 (2001) 849-857
32. Dingemanse J., and van Giersbergen P.L. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 43 (2004) 1089-1115
33. Kim K.A., and Park J.Y. Inhibitory effect of glyburide on human cytochrome P450 isoforms in human liver microsomes. Drug Metab Dispos 31 (2003) 1090-1092
34. Bièche I., Narjoz C., Asselah T., Vacher S., Marcellin P., Lidereau R., et al. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet Genomics 17 9 (2007) 731-742
35. Shimada T., Yamazaki H., Mimura M., Inui Y., and Guengerich F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270 (1994) 414-423
36. Forrester L.M., Henderson C.J., Glancey M.J., Back D.J., Park B.K., Ball S.E., et al. Relative expression of cytochrome P450 isoenzymes in human liver and association with the metabolism of drugs and xenobiotics. Biochem J 281 (1992) 359-368
37. Wedlund P.J. The CYP2C19 enzyme polymorphism. Pharmacology 61 (2000) 174-183
38. Nishimura M., Yaguti H., Yoshitsugu H., Naito S., and Satoh T. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 123 (2003) 369-375
39. Hakkola J., Pasanen M., Hukkanen J., Pelkonen O., Mäenpää J., Edwards R.J., et al. Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Biochem Pharmacol 51 (1996) 403-411
40. Syme M.R., Paxton J.W., and Keelan J.A. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 43 (2004) 487-514
41. Deshmukh S.V., Nanovskaya T.N., and Ahmed M.S. Aromatase is the major enzyme metabolizing buprenorphine in human placenta. J Pharmacol Exp Ther 306 (2003) 1099-1105
42. Deshmukh S.V., Nanovskaya T.N., Hankins G.D., and Ahmed M.S. N-demethylation of levo-alpha-acetylmethadol by human placental aromatase. Biochem Pharmacol 67 (2004) 885-892